anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an application of cell penetrating peptide LTA2 from an LT subunit in the aspect of serving as an intracellular drug delivery carrier. The sequence of the LTA2 is as shown in SEQ ID No: 1. The invention further provides a preparation method of a fusion protein drug. The fusion protein is obtained by connecting an LTA2 peptide fragment with protein used as a drug through connecting peptide Linker. According to the invention, a fact is found for the first time that the LTA2 peptide fragment has the functions of penetrating through cytomembrane and can carry such macromolecules as protein to enter a variety of cells in vivo in a cell endocytic manner, and the LTA2 peptide fragment is a trans-membrane delivery carrier of such bioactive molecules as protein and nucleic acid, which has a broad development prospect. The LTA2 has high penetrating efficiency, and the number of cationic amino acids is decreased, so that the LTA2 is safe and free of cell toxicity, and the potential unsafe factors are relatively few. Different from such previously found recombinant protein N end penetrating peptides as TAT, MPG and the like, the LTA2 disclosed by the invention is a C end cell penetrating peptide of recombinant protein, and a new choice is added in the aspect of designing cell penetrating recombinant protein drug protein.
This invention provides a method and a system for introducing a macromolecule into a target cell in vivo, which comprises obtaining three-dimensional structure images of an organ tissue located in the target cell and 3D vessel photo images of the organ tissue located in the target cell, by an image collecting unit; merging the structure image and the 3D vessel photo image by an image merging unit for selecting a vessel completely covering the target cell to be a delivering way of the macromolecule; injecting microbubble liquid (which can be ultrasonic developer or artificial blood) into the target cell by an injecting device through a catheter into the selected vessel delivering way; enforcing energy by an energy transforming model to produce biological effect of the microbubble in which a non-permanently hole is formed on a cell membrane of the target cell; and injecting a macromolecule desirable to introduce into the target cell by the injecting device through the selected vessel delivering way through which the macromolecule enters into the target cell by passing the broken of cell membrane. The method of this invention is using mergence of three-dimensional structure images and 3D vessel photo images of the organ tissue located by the target cell. For this, the target cell is positioned precisely for selecting a most effective vessel delivering way. By using this selected way, the macromolecule compound desirable to introduce into the target cell is injected through a catheter. Further, the membrane permeability is regulated by enforcing appropriate energy strength. The macromolecule compound enters the target cell by passing through the non-permanently hole on cell membrane. The method of this invention is especially suitable for use in gene transferring, gene therapy and drug delivering in local. The accuracy and effect can increase significantly.
The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
This study is designed to investigate whether filling the rectum with high density barium prior to a magnetic resonance spectroscopy (MRS) exam of the prostate improves the quality of the acquired spectrum. It is expected that the dense substance should help prevent air from entering the rectum and thus susceptibility artifacts in the obtained MRS data should be reduced. Ten patients with localized prostate cancer will be recruited for this study. There will be no change in treatment planning based on MRS study. Patient will receive standard radiation treatment prescribed by radiation oncologist.

An MRS study of each patient's prostate will be conducted with the 3 Tesla Philips Intera NMR (Nuclear Magnetic Resonance) scanners before and after filling the rectum with barium. Patients will be requested to take a mild laxative of their choice the night before the exam, and not to eat for 2-4 hours prior to the scan. To facilitate this, that patient's exam will be booked prior to lunch. Prior to the exam, the patient will be asked to empty their bladder and 40 mg of Buscopan will be administered to the patient (i.m. of i.v.) to reduce peristalsis, the presence of which degrades the quality of NMR scans. The patient will lie on a board designed to fit on the MR scanner patient bed and that holds one of the elements of the dual element phased array radiofrequency (RF) coil in place. The patient will be positioned such that the prostate is within the coil's field of view (preferably along its central axis); that is, the patient will lie on one element of the coil and the other element will be placed on top of the patients abdomen. An abdominal restraint will be placed around the patients abdomen to reduce breathing effects. After the patient has been centered in the magnet, MRI (Magnetic Resonance Imaging) images will be acquired to identify the tumor location. The positioning of the MRS voxel with the prostate will be carefully determined with the aid of a radiation oncologist. Preparation scans for the spectroscopy acquisition will be carried out prior to applying a PRESS (Point RESolved Spectroscopy) sequence that will be employed to obtain a proton (1H) spectrum of the prostate. The entire scan duration from preparation till completion will be approximately 30 minutes (5 minutes for patient positioning, 10 minutes for imaging and voxel placement, 5 minutes for spectroscope sequence preparation scans, and 10 minutes for spectrum acquisition). Following scan completion, the patient will have about 150 mL of Barium solution administered to the rectum. After standing for 3-4 minutes, the patient will like back on the NMR scanner bed and the same NMR procedure will be repeated again. The spectra acquired without and with the presence of Barium solution in the rectum will be compared to see if the latter situation is indeed advantageous.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates piracetam-base agents influencing on the central nervous system. Invention proposes nootropic agent made as injection solution and comprising piracetam as an active substance and the following accessory substances: sodium acetate, acetic acid and water for injection taken in the following ratio of components, wt. -%: piracetam, 15-25; sodium acetate, 0.08-0.11; acetic acid, up to pH = 5.8; water for injection, the balance. The preparation is stable in storage due to qualitative and quantitative ratio of components that provides the permanent therapeutic effect in the corresponding prescription. EFFECT: enhanced effectiveness of agent. 1 ex
The present invention concerns a novel aryl derivative or the pharmaceutically acceptable salt thereof which has an excellent blood sugar decrease action, and can treat and/or prevent the sugar and the lipid metabolic disease or the peroxysome activation receptor(PPAR) γ intermediate disease. The present invention concerns a novel aryl derivative of the following formula (I) E-A-Y(I) [wherein, E represents a group of the formula -CH2NHCOR1, a group of the formula -CH(CH3)NHCOR1(R1 represents a C6-C10 aryl group which may be independently substituted with 1 to 5 groups selected from substituents a etc. )etc. ; A represents a group of the formula (II), a group of the formula (III) or a group of the formula (IV)(R2 represents a hydrogen atom, a halogen atom etc. , R3 represents a hydrogen atom, a halogen atom etc. , R4 represents a C1-C6 alkyl group; V represents a group of the formula =CH-etc. ; Z represents a group of the formula =CH-etc. ; Q represents a group of the formula =CH-etc. ; CE and CY represents a single bond; CE is bond to the group of the formula E; CY is bond to the group of the formula Y; Y represents a group of the formula -NHSO2R5, a group of the formula -CH2OR5(R5 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be independently substituted with 1 to 5 groups selected from substituents a etc. )etc. ; substituents a represents a halogen atom, a C1-C6 alkyl group or a hydroxyl C1-C6 alkyl group etc. )etc. ], or the pharmaceutically acceptable salt thereof.
Cancer is a leading cause of death and disability in children under 15 years of age. Its unrelieved symptoms and side effects of often-aggressive treatments can lead to poor psychosocial functioning and decreased health-related quality of life (HRQOL) for patients and their families. Barriers at the patient, healthcare provider and system levels can contribute to poor symptom management. A technology-based program can minimize these barriers by routinely collecting and interpreting patient-reported outcomes (PROs) and patient/parent contextual data in pediatric oncology ambulatory settings in a manner that is efficient, actionable by physicians, supports engagement of patients and families with their health and care, and improves clinical processes and outcomes. This proposed project will develop and evaluate the effectiveness of such a program: Symptom Monitoring \& Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS). We hypothesize that the SyMon-SAYS intervention will decrease parent-perceived barriers to managing their child's symptoms, decrease patient symptom burden, increase patients' and parents' self-efficacy, and ultimately increase patient HRQOL.
Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated.
The invention relates to medicine and can be used in neurology, traumatology, physiotherapy and orthopedics. The method is implemented in stages. In the first stage, intravenous laser irradiation of the blood in the ultraviolet and red spectra of low-intensity laser radiation is performed. Then, traction of the spine on a traction apparatus is performed. The second stage comprises two alternating series of procedures which are performed in succession. In the first series of procedures, a vacuum cup massage is performed on the patients. Then, hirudotherapy is performed by means of applying a leech/leeches in the region of the patient's navel. Then, swing therapy is performed on a "SWING MACHINE" eletromechanical trainer. In the second series, acupressure therapy of the muscle structure of the spine is performed on the patients. Then, there is manual therapy on the ligament and muscular system of the spine and joints during. Then, the swing therapy is performed on the "SWING MACHINE" eletromechanical trainer. Then, hirudotherapy is performed by means of applying a leech/leeches in the region of the patient's spine. On other days on which there is no manual therapy or hirudotherapy in the spine region, physical exercises are performed after the swing therapy. In the third stage, foot pathology diagnostics are performed on the patients. The technical result consists in increasing the effectiveness of the treatment of diseases of the spine.
The invention provides a pharmaceutical composition capable of strengthening the immunity of poultry. The pharmaceutical composition comprises, by weight, from 5 to 15 parts of butafosfan, from 1 to 10 parts of astragalus polysaccharide and the balance adjuvant materials, and the astragalus polysaccharide is extracted by a method including steps of water boiling backflow and ethanol precipitation. By the pharmaceutical composition, both a cellular immunity level and a humoral immunity level of a poultry organism are obviously improved, particularly, the cellular-level immunity of the poultry organism is strengthened, and accordingly the integral immunity of the poultry organism is effectively strengthened. In addition, by using the pharmaceutical composition with a vaccine, avian antibody titer can be increased, the quantity of generated antibodies is high, the antibodies can be maintained for a long time, and an immunopotentiation effect is obvious. Accordingly, the pharmaceutical composition can be used for cooperative medication for avian Newcastle diseases, bursa of Fabricius, avian influenza and the like, antibody protection time is prolonged, the usage and the usage count of vaccines are reduced, and prevention and treatment effects of the vaccines are improved. The pharmaceutical composition can be used for preventing sudden and serious avian diseases, and accordingly prevalence of common avian diseases is avoided.
Prior to injection, reconstitute each vial of XEOMIN with sterile, preservative-free 0.9% Sodium Chloride Injection, USP [see Dosage Form and Strengths (3)]. A 20-27 gauge short bevel needle is recommended for reconstitution. Draw up an appropriate amount of preservative-free 0.9% Sodium Chloride Injection, USP into a syringe (see Table 5). Clean the exposed portion of the rubber stopper of the vial with alcohol (70%) prior to insertion of the needle. After vertical insertion of the needle through the rubber stopper, the vacuum will draw the saline into the vial. Gently inject any remaining saline into the vial to avoid foam formation. If the vacuum does not pull the saline into the vial, then XEOMIN must be discarded. Remove the syringe from the vial and mix XEOMIN with the saline by carefully swirling and inverting/flipping the vial – do not shake vigorously. Reconstituted XEOMIN is a clear, colorless solution free of particulate matter. Do not use XEOMIN if the reconstituted solution has a cloudy appearance or contains floccular or particulate matter.

After reconstitution, use XEOMIN for only one injection session and for only one patient. Administer reconstituted XEOMIN within 24 hours after dilution. During this time period, store unused reconstituted XEOMIN in the original container in a refrigerator 2°C -8°C (36°F -46°F) for up to 24 hours until time of use. XEOMIN vials are for single-dose only. Discard any unused portion.

Diluent volumes for reconstitution of XEOMIN are indicated in Table 5.
A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.
Seborrheic dermatitis (SD) is a common skin disease with signs and symptoms that may vary by skin color, associated medical conditions, environmental factors, and vehicle preference. Diagnosis of SD is based on presence of flaky, "greasy" patches, and/or thin plaques accompanied by erythema of the scalp, face, ears, chest, and groin and is associated with pruritus in many patients. The presentation may vary in different skin types and hyper- or hypopigmentation may occur, with or without erythema and minimal or no scaling. While the pathogenesis is not certain, 3 key factors generally agreed upon include lipid secretion by sebaceous glands, Malassezia spp. colonization, and some form of immunologic dysregulation that predisposes the patient to SD. Treatment involves reducing proliferation of, and inflammatory response to, Malassezia spp. Topical therapies, including antifungal agents and low potency corticosteroids, are the mainstay of treatment but may be limited by efficacy and side effects. Few novel treatments for SD are currently being studied; however, clinical trials assessing the use of topical phosphodiesterase-4 inhibitors have been completed. Improving outcomes in SD requires recognizing patient-specific manifestations/locations of the disease, including increased awareness of how it affects people of all skin types.
Mycetoma is a neglected tropical disease (NTD) with devastating morbidity and stigma. Despite increased awareness and international collaboration, the burden of mycetoma is largely unknown and diagnosis and treatment are difficult. Addressing mycetoma globally aligns with several United Nation's Sustainable Development Goals (SDGs). Little progress has been made since the WHO's NTD roadmap publication in 2020. The Global Mycetoma Working Group proposes an enhanced mycetoma-control roadmap to meet the SDGs, stimulate progress and improve the lives of patients experiencing mycetoma. By aligning mycetoma management with the goals and targets of this enhanced roadmap, it becomes possible to leverage existing resources, infrastructure and partnerships to improve the lives of affected individuals and communities. This updated assessment is designed for the benefit of health workers and providers in mycetoma-endemic areas, NTD government officials, civil society and funding and implementing agencies.
Deficiency of adenosine deaminase 2 (DADA2) is a monogenic disease caused by biallelic mutations in adenosine deaminase 2 (ADA2). The varying phenotypes of the disease often lead to delayed diagnosis or misdiagnosis. We report an 11-year-old boy with DADA2 and provide a preliminary analysis of genotype-phenotype correlation. The age of onset of the disease was 8 years old. The disease successively involved the brainstem, muscles, joints, and cerebrum. After three relapse-remission episodes over 3 years, the patient was finally diagnosed with DADA2 by whole-exome sequencing. Compound heterozygous variants in the ADA2 gene (NM_001282225.2: c.1072G>A, p.Gly358Arg; c.419dupC, p.Arg141Lysfs*37) were found in the patient. He did not receive anti-TNF therapy and had no relapse after a 8-month follow-up. We identified a novel variant of the ADA2 gene, and the associated disease course may follow a relapse-remission pattern. Homozygous mutations of p.Gly358Arg can cause pure red cell aplasia, whereas compound heterozygous variations may lead to different phenotypes. Variants in the catalytic domain and frameshift mutations may also cause relatively benign phenotypes besides causing hematological disorders. Further studies are needed to clarify the genotypic-phenotypic relationship of this disease.
STUDY OBJECTIVES: The coronavirus disease pandemic has highlighted disparities in health care. Parents assist in sickle cell disease management in children. Understanding sleep in parents of children who are diagnosed with sickle cell disease is an important facet of disease management. Our objectives were to identify sleep characteristics of parents of children with sickle cell disease age 18 years or younger during the coronavirus disease pandemic, to investigate measures used by parents to achieve restful sleep, and to discuss how sleep may be improved in parents of children diagnosed with sickle cell disease.
METHODS: This study conducted 14 face-to-face semistructured interviews with parents of children diagnosed with sickle cell disease. A majority of the interviews (93%) were conducted at a hematology clinic. Qualitative thematic analysis was used to analyze data.
RESULTS: All parents reported that their child experienced pain because of sickle cell disease. Most parents (86.7%) reported that their child was diagnosed with sickle cell anemia. Four themes were identified: difficulty obtaining restful sleep during their child's sickle cell crisis, sleep during the coronavirus disease pandemic, factors affecting sleep, and effects of sleep disturbance and deprivation on parental performance.
CONCLUSIONS: This research has highlighted some of the difficulties experienced by parents of children who are diagnosed with sickle cell disease and allows for additional insight into the sleep experiences of parents as they attempt to manage their child's disease.
CITATION: Osborne JC, Odlum M, Sedrak A. Sleep experiences of parents of children 18 years or younger with sickle cell disease during the COVID-19 pandemic: a qualitative study. J Clin Sleep Med. 2024;20(5):777-782.
The efficacy of cisatracurium besylate to provide skeletal muscle relaxation to facilitate tracheal intubation was established in studies in pediatric patients aged 1 month to 12 years old. In these studies, patients had general anesthesia and mechanical ventilation.

In Study 6, a cisatracurium besylate dose of 0.1 mg/kg was evaluated in 16 pediatric patients (ages 2 years to 12 years) during opioid anesthesia. When administered during stable opioid/nitrous oxide/oxygen anesthesia, maximum neuromuscular blockade was achieved in an average of 2.8 minutes (range: 1.8 to 6.7 minutes) with a clinically effective block for 28 minutes (range: 21 to 38 minutes).

In Study 7, a cisatracurium besylate dose of 0.15 mg/kg was evaluated in 50 pediatric patients (ages 1 month to 12 years) during opioid anesthesia. When administered during stable opioid/nitrous oxide/oxygen anesthesia, maximum neuromuscular blockade was achieved in an average of about 3 minutes (range: 1.5 to 8 minutes) with a clinically effective block for 36 minutes (range: 29 to 46 minutes) in 24 patients ages 2 to 12 years. In 27 infants (1 to 23 months), maximum neuromuscular block was achieved in about 2 minutes (range: 1.3 to 4.3 minutes) with a clinically effective block for about 43 minutes (range: 34 to 58 minutes) with this dose.

Study 7 also evaluated intubating conditions in 180 pediatric patients (ages 1 month to 12 years) after administration of cisatracurium besylate doses of 0.15 mg/kg following induction with either halothane (with halothane/nitrous oxide/oxygen maintenance) or thiopentone and fentanyl (with thiopentone/fentanyl nitrous oxide/oxygen maintenance). Table 13 displays the intubating conditions by type of anesthesia, and pediatric age group. Excellent or good intubating conditions were produced 120 seconds following 0.15 mg/kg of cisatracurium besylate in 88/90 (98%) of patients induced with halothane and in 85/90 (94%) of patients induced with thiopentone and fentanyl. There were no patients for whom intubation was not possible, but there were 7/120 patients aged 1 year to 12 years old for whom intubating conditions were described as poor.

Table 13: Intubating Conditions at 120 Seconds* in Pediatric Patients Ages 1 Month to 12 Years Old in Study 7

*Excellent: Easy passage of the tube without coughing. Vocal cords relaxed and abducted.

Good: Passage of tube with slight coughing and/or bucking. Vocal cords relaxed and abducted.

Poor: Passage of tube with moderate coughing and/or bucking. Vocal cords moderately adducted. Response of patient requires adjustment of ventilation pressure and/or rate.
Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
Data of previous studies have shown that counts of urinary T lymphocyte subsets correlate with disease activity in several immunological renal diseases, e.g. ANCA-associated glomerulonephritis. Thus, study authors hypothesise that CD4+, respectively CD8+, T effector memory lymphocytes found in urine samples of patients with inactive ANCA-vasculitis predict subsequent renal flares. Therefore, quantification of these cellular subsets might reliably predict relapse of ANCA associated glomerulonephritis at an early stage. In a prospective experimental study urine of patients with ANCA-vasculitis and no renal involvement or patients in renal remission will be analysed by flow cytometry. After 6 months of observation, clinical outcome and potential renal relapse will be determined and correlated to initial T lymphocyte count.